Baird Starts Idenix Pharmaceuticals Inc. (IDIX) at Neutral; No Great Pipeline but Patents Could Have Value

Article Stock Quotes (2) Comments (0)

After the close, Baird initiated coverage on Idenix Pharmaceuticals Inc. (NASDAQ: IDIX) with a Neutral and $5 price tarrget.

With a focus on Hepatitis C, the firm does not find the company's pipeline particularly compelling, from an investment standpoint. That said, they view the company's patent estate as a wild card with a potential for economic interest in Gilead's (NASDAQ: GILD) Hep C programs.

For an analyst ratings summary and ratings history on Idenix Pharmaceuticals Inc. click here. For more ratings news on Idenix Pharmaceuticals Inc. click here.

Shares of Idenix Pharmaceuticals Inc. closed at $4.73 yesterday, with a 52 week range of $3.35-$12.68.

---

Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW

---

*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here

---

---

You May Also Be Interested In

• Deutsche Bank Resumes CenterPoint Energy (CNP) at Hold
• Deutsche Bank Starts Kodiak Oil & Gas (KOG) at Hold
• Topeka Capital Starts Diodes (DIOD) at Buy

Create E-mail Alert Related Categories

New Coverage

Related Entities

Robert W Baird

Add Your Comment

Name

Subject

Body

Share on Facebook

Verification
can't see the text?
click here to refresh the image.
what's this?